bioMérieux SA

North Carolina has quietly emerged as one of the nation's most formidable life sciences ecosystems, anchored by its position as the leading biomanufacturing hub in the United States. With more than 860 life sciences companies employing over 76,000 people across the state, North Carolina offers a unique combination of world-class research institutions, a robust manufacturing workforce, and strategic East Coast positioning that continues to attract both established medtech leaders and emerging innovators. The state has significant benefits for manufacturers , even being named top in the nation by the Site Selection Group in 2024. North Carolina maintains one of the lowest corporate income tax rates in the U.S., currently at 2.5%. In addition, state and local governments in the area offer economic incentives, including grants and tax breaks, to attract new investments. Major firms like Genentech, Eli Lilly, FUJIFILM Diosynth, and Novo Nordisk already had facilities in the state, and since July 2024, Japan’s Nipro Medical Corp. has announced that it will build its first North American manufacturing facility in Greenville, NC, Netherlands-based Nelipak, a supplier of rigid and flexible packaging for healthcare and other demanding applications, opened its first North American flexible packaging production site in the state, Johnson & Johnson broke ground on a facility, and GMAX Industries Inc., a manufacturer of medical disposables, chose to locate its base of manufacturing operations in Winston-Salem. As the medical device and diagnostics industries navigate post-pandemic supply chain challenges, increased demand for reshoring, and rapid technological advancement, North Carolina's diversified ecosystem, which spans biopharmaceuticals, medical devices, diagnostics, and agricultural technology, positions the state as a compelling alternative to traditional hubs like Massachusetts, California, and Minnesota. MD+DI connected with Christopher Chung, CEO of the Economic Development Partnership of North Carolina, to discuss what sets North Carolina apart in the increasingly competitive landscape of medtech site selection, how the state is building its talent pipeline to meet industry demands, and where he sees the greatest opportunities for growth in the years ahead. North Carolina is recognized as the #1 biomanufacturing hub in the nation, but how would you characterize the state's position in the medical device and diagnostics sectors specifically? What differentiates North Carolina's medtech ecosystem from other established hubs like Massachusetts, California, or Minnesota? Chung: I would characterize North Carolina as a leader in medical devices and diagnostics. NCBiotech, a non-profit organization that supports North Carolina’s life sciences industry, counts more than 160 device and diagnostic companies in the state, including Aptyx in Charlotte, bioMérieux in Durham, and Labcorp in Burlington. We’re also seeing significant new investment from companies like ESSERT Robotics, Ypsomed, and Nipro Medical. What separates North Carolina from other major medtech hubs is that we have both sides of the equation: the research talent to develop new technologies and the manufacturing workforce to bring them to market. Five Tier-1 research universities in North Carolina produce more than 6,000 biological and biomedical graduates each year, and our state has the largest manufacturing workforce in the Southeast. That combination of research, talent and manufacturing expertise gives companies a unique advantage when they’re deciding where to grow. You have 860+ life sciences companies employing 76,000+ people in the state. Can you break down the composition of that ecosystem—how much is biopharm versus medtech versus diagnostics? Where are you seeing the most growth? Chung: North Carolina’s life sciences ecosystem is broad and continues to grow. More than 860 companies employ over 76,000 people across the state, with biopharmaceutical manufacturing representing the largest segment at nearly 34,000 employees across 108 facilities. Clinical research accounts for another 24,000 workers, while medical devices and diagnostics include more than 160 companies and agtech adds more than 180 companies. What’s particularly encouraging is the pace of that growth. Since 2021, pharmaceutical and medicine manufacturing employment has grown 12% in North Carolina (compared with 6% nationally), while medical device employment has grown 5% (more than twice the national rate). That tells us the state’s life sciences economy isn’t simply growing in one area. We’re seeing momentum across the ecosystem, and that diversification is one of North Carolina’s greatest strengths. What trends are you seeing in life science and advanced manufacturing investments coming into North Carolina? Are companies primarily expanding existing operations, or are you attracting new entrants to the state? Chung: North Carolina has a diversified life sciences sector, both in terms of the products being developed and manufactured here and where companies are located across the state. If I had to point to one area with real momentum right now, it would be GLP-1 weight-loss drugs. We’re seeing investment in both the drugs themselves and the ancillary products that support them. Novo Nordisk is a great example, announcing two years ago one of the largest investments in its history – $4.1 billion and 1,000 new jobs at its Johnston County operation. We continue to see both new companies come to North Carolina and existing companies make significant investments to grow here. Post-pandemic, we've seen significant reshoring and supply chain diversification efforts in medical devices and diagnostics. How is North Carolina positioned to capture that investment, and what are companies telling you they need from the state to make those decisions? Chung: North Carolina is well-positioned because we’re not starting from scratch. We already have a deep bench of medical device and diagnostics manufacturers, along with a strong contract manufacturing base to support them. When companies are looking to bring production closer to home, they’re primarily asking whether they can find the workforce they need, get into a building or break ground quickly, and have confidence in the regulatory and permitting process. Capital costs obviously matter, but increasingly, the deciding factor is whether we can show a company a credible path to getting its facility staffed and operational. Our location is a major asset, too – the midpoint location of the East Coast gives us reach to several major markets within hours. Global medtech leaders like BD, Teleflex, and bioMérieux have significant operations in North Carolina. What initially attracted these companies to the state, and what keeps them expanding there rather than relocating to other regions? Chung: BD, Teleflex, and bioMérieux have all been part of North Carolina’s life sciences story for decades. What initially attracted them was the Research Triangle and its proximity to our world class universities producing the talent they needed to grow. What keeps them here is the cluster that has developed in the Triangle. When you have major life sciences companies operating in the same region, it becomes easier to recruit specialized talent, grow supplier networks, and build the infrastructure the industry needs. That creates a cycle where companies that are already here continue to see opportunities to grow. Workforce is often cited as a critical factor in site selection decisions. How is North Carolina addressing the talent pipeline for medtech, particularly in areas like precision manufacturing, quality systems, and regulatory affairs? Chung: Workforce is often the number one factor companies consider when deciding where to invest, and North Carolina has made significant investments in building that pipeline. Our community college system does a tremendous amount of heavy lifting in this area. BioWork, for example, gives people with no prior science background a pathway into life sciences manufacturing careers in about 152 hours of training and is offered at several community college campuses across the state. We’re also continuing to invest in specialized training infrastructure, including a new life sciences training center at Durham Tech. There is more work to do, but North Carolina has the institutions and partnerships in place to keep building the talent pipeline as the industry evolves. Looking ahead, what are the biggest opportunities and challenges for North Carolina's medtech sector? Are there specific subsectors – surgical robotics, digital health, diagnostics – where you see the state having a competitive advantage? Chung: The biggest opportunity is that North Carolina already has the ingredients needed for the next generation – world-class research universities, an established base of device and diagnostics manufacturers, and growing momentum in digital health and AI-enabled diagnostics. No matter the focus area, the challenge is making sure our workforce keeps pace with demand, particularly for specialized engineering, quality and regulatory talent. Our job as economic developers is to make sure North Carolina remains a place where companies can find the talent they need to grow.

Point of Care Molecular Diagnostics Market to Surge from $ 5.06 Billion in 2026 to $ 12.44 Billion by 2035-By CLIA-Waiver Expansion, BARDA Stockpiling Programs NY, CA, UNITED STATES, August 12, 2026 / EINPresswire.com / -- As per Market Research Future, the global Point of Care Molecular Diagnostics Market size to reach USD 12.44 Billion by 2035 from USD 5.06 Billion in 2026, at a CAGR of 10.5% during the forecast period 2026--2035. The market base was estimated at USD 4.58 Billion in 2025. The 10.5% CAGR--anchored by structural demand for rapid, decentralized nucleic-acid testing rather than discretionary healthcare spending--is driven by three converging forces: accelerated CLIA-waiver expansion for molecular panels that has extended point-of-care molecular testing into physician offices and retail pharmacies, sustained BARDA and public-health stockpiling programs that have de-risked R&D investment and compressed per-test pricing, and the broadening of decentralized testing infrastructure that has shifted molecular diagnostics from centralized batch-PCR workflows to sample-to-answer cartridge systems delivering results in under 30 minutes. Request A Free Sample: https://www.marketresearchfuture.com/sample_request/11484 Key Market Trends & Growth Drivers CLIA-Waiver Expansion for Molecular Panels Between 2022 and 2024, 14 novel molecular assays were given CLIA-waived status by the U.S. Centers for Medicare & Medicaid Services (CMS), allowing physician offices and retail pharmacies to conduct tests without a laboratory director present. For the Point of Care Molecular Diagnostics Market, each waiver increases the addressable install base by an estimated 45,000 potential testing facilities in the US alone. This directly translates into additional cartridge pull-through income. CMS reimbursement rates for waived molecular testing now vary from USD 45 to USD 142 per test. There are considerable financial incentives for decentralized adoption because the U.S. now encompasses more than 220,000 certificate-of-waiver sites. Each percentage point of CLIA-waiver expansion translates into measurable prescription volume for point-of-care molecular diagnostics, and the decentralized testing schedule embedded in routine care makes this driver structurally durable through 2035. BARDA and Public-Health Stockpiling Programs Legacy centralized laboratory workflows, which required batch PCR runs and 24--48-hour turnaround, are giving way to sample-to-answer cartridge systems that deliver nucleic-acid-level sensitivity in under 30 minutes at the bedside. Lyophilized reagent chemistries that tolerate ambient shipping have slashed cold-chain costs by an estimated 35%, while cloud-connected instrument dashboards use predictive analytics to preempt maintenance downtime. Between 2021 and 2025, firms that can scale cartridge production to surge-capacity levels within 72 hours of a proclaimed public health emergency will receive USD 650 million from BARDA's Rapid Diagnostics for Infectious Disease program. In addition to attracting new players to the Point of Care Molecular Diagnostics Market and locking in minimum-order guarantees that de-risk R&D investment, this procurement strategy has increased competition and reduced per-test pricing by about 18% since 2021. Decentralized Testing Infrastructure and Reimbursement Reform CMS reimbursement under CPT codes 87631--87633 incentivizes emergency departments and urgent-care chains to adopt molecular respiratory panels, while pharmacy giants CVS and Walgreens have piloted in-store molecular STI testing in select states. NHS England's pledge to deliver 160 community diagnostic centres by 2025 has created a procurement pipeline exceeding GBP 350 Million for rapid molecular platforms. European data from antimicrobial-stewardship programs show that rapid molecular POC testing reduces inappropriate antibiotic prescriptions by up to 30%, saving payers approximately USD 2,000--5,000 per patient in downstream resistance-management costs. This economic incentive has driven hospital formulary committees to prioritize rapid molecular POC protocols, shifting procurement budgets toward the Point of Care Molecular Diagnostics Market at the expense of send-out reference-lab spending. Ask for Customization: https://www.marketresearchfuture.com/ask_for_customize/11484 Market Segment Insights BY PRODUCT & SERVICE Assays & Kits: Dominant segment with ~79% revenue share in 2025. Reflecting the recurring consumable-driven business model that sustains installed-base economics. Multiplex respiratory panels--combining influenza A/B, RSV, and SARS-CoV-2--drove the majority of consumable revenue in 2024, with average selling prices ranging from USD 28 to USD 55 per cartridge depending on target count. Hospital procurement teams treat cartridge contracts as default first-line supply agreements, and volume pricing has enabled broad adoption even in cost-sensitive emerging markets. Instruments / Analyzers: Fastest-growing product segment at 12.9% CAGR (2026--2035). Driven by next-generation platform refresh cycles that reduce per-test footprint and capital cost. List prices for sample-to-answer molecular analyzers range from USD 25,000 to USD 65,000, making them unaffordable for remote clinics without grant support. The economics of the Point of Care Molecular Diagnostics Market will increasingly mirror the inkjet-printer model: low-margin or subsidized instrument placements funded by high-margin, annuity-like cartridge revenues. Manufacturers that lock in multi-year reagent-rental contracts at health-system scale will build switching-cost moats that concentrate market share among the top five players over the next decade. BY APPLICATION Infectious Diseases: Dominant application with ~74% revenue share in 2025. Approximately driven by respiratory-panel and STI-testing volumes. The inherent clinical-utility case for rapid molecular confirmation at the point of care makes infectious-disease testing a near-universal component of POC molecular care pathways. Respiratory and sexually transmitted infections present the clearest demand for decentralized molecular diagnostics. Oncology: Fastest-growing application segment at 15.2% CAGR (2026--2035). Reflecting liquid-biopsy companion diagnostics moving closer to the bedside. Liquid-biopsy technologies that detect circulating tumor DNA are migrating from central-lab reference workflows toward compact analyzers capable of delivering actionable results during a single clinic visit. Immune checkpoint inhibitors extending median overall survival create a larger prevalent population requiring sustained molecular monitoring. BY TECHNOLOGY PCR-Based: Dominant technology with ~75% revenue share in 2025. Underpinned by decades of clinical validation and broad regulatory acceptance across FDA, CE-IVDR, and PMDA pathways. Hospital infusion center infrastructure dominates volume, channeling routine PCR-based platform supply. PCR-based systems delivered in hospital outpatient settings anchor this segment. Isothermal Nucleic-Acid Amplification Technology (INAAT): Fastest-growing technology segment at 15.1% CAGR (2026--2035). Convenience and resource-limited setting deployment drive demand. INAAT technologies--including loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA)--eliminate the need for thermal cycling hardware, enabling deployment in field settings where electricity supply is intermittent. This technology-driven adoption is expected to open up incremental revenue for the Point of Care Molecular Diagnostics Market in settings lacking full laboratory infrastructure. BY END USER Hospitals: Largest segment with ~59% share in 2025. Comprehensive emergency-department and ICU testing requirements dominate volume. Hospitals remain the primary delivery site for point-of-care molecular diagnostics due to infection-control infrastructure, specialized waste disposal, and regulatory licensing requirements. Rapid turnaround of respiratory and sepsis panels directly influences patient disposition and antimicrobial prescribing. Read Detailed Insights: https://www.marketresearchfuture.com/reports/point-of-care-molecular-diagnostics-market-11484 Regional Outlook North America -- Dominant Market (~46.5% Share, 2025) The United States generates approximately 82% of North American Point of Care Molecular Diagnostics Market revenue, driven by the mature CLIA-waiver ecosystem that now encompasses more than 220,000 certificate-of-waiver sites, CMS reimbursement codes under CPT 87631--87633, and BARDA stockpiling programs--a single policy ecosystem that converted a reference-lab-dominated market into one with a structural decentralized testing tail. Europe -- Second Largest (25.2% Share, 2025) Europe's Point of Care Molecular Diagnostics Market reflects divergent national strategies--Germany leads regionally with strong lab-network decentralization policies, contributing 28% of regional share, while the UK historically used selective centralized testing before broadening coverage through NHS community diagnostic-centre rollout at 11.4% CAGR. France contributes ~18.5% of regional share through biologie délocalisée regulatory expansion at USD 0.18 Billion in 2025. Italy contributes on national antimicrobial-stewardship mandates at 9.8% CAGR. Spain is growing at steady pace on regional health-authority procurement at USD 0.09 Billion in 2025. Asia-Pacific -- Fastest-Growing Region (14.2% CAGR, 2026--2035) Asia-Pacific is the engine of the Point of Care Molecular Diagnostics Market. China holds the largest regional share with ~32% of regional revenue, driven by NMPA fast-track approvals and domestic manufacturing scale-up. India is growing at 16.1% CAGR on the back of RNTCP molecular rollout and Ayushman Bharat scheme expansion. Japan contributes USD 0.14 Billion through PMDA reimbursement reforms at steady pace. South Korea is growing at 12.5% CAGR on national infectious-disease preparedness. Middle East & Africa -- Emerging Opportunity (USD 0.20 Billion, 2025) The Middle East & Africa is bifurcated between well-funded Gulf states and resource-constrained Sub-Saharan nations. Saudi Arabia leads the region with Vision 2030 healthcare modernization, contributing ~26% of regional share--NEOM health cluster and the UAE's Cleveland Clinic and Mayo Clinic affiliations have created pockets of excellence for point-of-care molecular diagnostics. The UAE is growing at 12.8% CAGR on medical-tourism diagnostic infrastructure. South Africa contributes USD 0.05 Billion on National Health Laboratory Service POC program. South America -- Growing Presence (USD 0.23 Billion, 2025) Brazil anchors South America's Point of Care Molecular Diagnostics Market at ~58% of regional revenue, with the Unified Health System (SUS) incorporating three new molecular POC procedure codes in 2024--enabling reimbursement for tuberculosis, HIV viral-load, and HPV genotyping at primary-care facilities--providing a stable demand floor that smooths regional forecasts. Access to advanced multiplex panels remains limited by import dependencies, though the Brazilian health ministry has initiated domestic cartridge production feasibility studies. Argentina is growing at 11.3% CAGR on dengue and Chagas screening programs. Competitive Landscape and Recent Developments The Point of Care Molecular Diagnostics Market exhibits medium concentration, with the top five companies capturing an estimated 60--68% of global revenue. The Herfindahl-Hirschman Index sits in the 1,200--1,500 range, reflecting a competitive field where two platform leaders hold significant share while a tier of mid-cap specialists competes aggressively on menu expansion and geographic reach. Patent expirations and generic reagent entry are gradually fragmenting branded segments, though pipeline innovation in CRISPR-based and isothermal platforms sustains competitive moats for first-movers. The competitive landscape is stratified between PCR-based platform pioneers serving global point-of-care molecular diagnostics markets, syndromic panel expansion specialists capturing respiratory and STI tenders, and isothermal amplification developers consolidating the resource-limited setting segment. KEY COMPANIES AND RECENT MILESTONES Cepheid (Danaher Corporation) (March 2025): Received FDA 510(k) clearance for a 4-in-1 Xpert Xpress respiratory panel combining Flu A/B, RSV, and SARS-CoV-2 with a 36-minute turnaround, expanding its hold on the Point of Care Molecular Diagnostics Market emergency-department segment. Broadest cartridge menu; dominant in hospital ED and TB programs. Holding ~18--22% of global revenue. Abbott Laboratories (January 2025): Launched the ID NOW 2.0 platform with cloud-connectivity features and a redesigned cartridge interface, targeting 15% faster workflow throughput. Speed-to-result leader; pharmacy and urgent-care focus. Holding ~15--19% of global revenue. Roche Diagnostics (October 2024): Expanded the cobas Liat menu to include Group A Streptococcus and Influenza A/B+RSV, adding four new CLIA-waived assays in a single regulatory submission. Integrated diagnostics ecosystem; strong payer relationships. Holding ~12--16% of global revenue. Hologic, Inc. (June 2024): Announced a USD 250 Million investment in manufacturing capacity for Panther Fusion consumables at its San Diego facility, anticipating sustained demand growth. Women's health molecular leadership; STI testing. Holding ~8--11% of global revenue. bioMérieux SA (February 2024): Entered a strategic partnership with the Global Fund to supply BioFire FilmArray systems to 23 sub-Saharan African countries under preferential pricing terms. Syndromic panel pioneer; antimicrobial stewardship positioning. Holding ~7--10% of global revenue. Future Outlook: 2026--2035 By 2030, precision molecular theranostics will become the operating system of infectious disease and oncology management. The convergence of companion diagnostics and targeted therapy will reshape the Point of Care Molecular Diagnostics Market through the late 2020s. By 2030, an estimated 40% of newly diagnosed infectious disease cases in high-income countries will undergo rapid molecular POC confirmation followed by matched antimicrobial therapy, creating a diagnostic-therapeutic revenue loop. The Global Fund's 2026--2028 replenishment cycle targets USD 18 Billion in total commitments, with molecular diagnostics designated a top-three procurement priority. Machine-learning models that integrate genomic, proteomic, and imaging biomarkers can recommend optimal sequencing of PCR-based, isothermal, and CRISPR-based diagnostics for individual patients. Start-ups have raised over USD 800 million in venture funding for AI-enabled diagnostic decision-support tools since 2023. More Related Research: https://www.marketresearchfuture.com/reports/cardiovascular-devices-market-11859 https://www.marketresearchfuture.com/reports/biosurgery-market-6246 https://www.marketresearchfuture.com/reports/anti-venom-market-5859 https://www.marketresearchfuture.com/reports/ophthalmic-device-market-43121 https://www.marketresearchfuture.com/reports/blood-screening-market-6899 https://www.marketresearchfuture.com/reports/pharmacy-market-12003 https://www.marketresearchfuture.com/reports/livestock-monitoring-market-22746 https://www.marketresearchfuture.com/reports/patient-monitoring-devices-market-2484 https://www.marketresearchfuture.com/reports/bariatric-surgery-market-5693 https://www.marketresearchfuture.com/reports/veterinary-animal-vaccines-market-2687 Larry Wilson WantStats Research And Media Pvt. Ltd. +1 855-661-4441 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants. The PGDx elio tissue complete CDx is now approved in the U.S. to help identify patients with advanced melanoma, the deadliest type of skin cancer, who may benefit from targeted treatments. The diagnostic is specifically designed to help identify patients with BRAF V600E or V600K variants who may be eligible for FDA-approved targeted therapies. Those include BRAF inhibitors such as Novartis’ Tafinlar and Roche’s Zelboraf for patients with BRAF V600E mutations, as well as BRAF/MEK inhibitor combination regimens for patients with V600E or V600K mutations. The kit-based test can be performed in hospitals and clinical laboratories and uses next-generation sequencing to detect BRAF V600E and V600K mutations in melanoma. It uses high-throughput hybridization-based capture technology to analyze DNA isolated from formalin-fixed, paraffin-embedded tumor tissue. Around half of all cutaneous melanomas carry a BRAF mutation, with the majority of these being V600E. Labcorp said in an Aug. 10 release that hospitals and health systems using the kit can retain samples and data “that may inform future clinical research.” “Advanced melanoma is an extremely aggressive and life-threatening cancer, but targeted treatments are offering real hope for patients,” said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp, in a statement. “Labcorp's FDA-approved companion diagnostic improves access to these therapies by allowing clinicians to confirm which patients may be eligible for and can start receiving those treatments as soon as possible.” Several other tests already exist to detect BRAF mutations in melanoma, including Foundation Medicine’s FoundationOne CDx and Caris Life Sciences’ MI Cancer Seek, as well as Roche’s cobas 4800 BRAF V600 Mutation Test and bioMérieux’s THxID BRAF test.